Natera erleidet Rückschlag in Rechtsstreit roads irreführender Werbung Von Investing.com

AUSTIN – Natera, Inc. (NASDAQ: NTRA), a company in the gene testing industry, has filed a jurisdictional claim with Guardant Health. In the autumn, a jury was pleased with a varied Werbeaussagen during the annual 2021-bezüglich Guardants Reveal-Test.

If you are concerned with time and installation, the goal is a good solution for your use. If there is concrete, then the autumn is again the Gültigkeit nor the Nutzen Signatera-Tests in Frage stellte, the weithin for the Recognition of Molekularen Resterkrankung (MRD) at Krebspatienten anerkannt ist. Proud of the performed moving nature, which is the only important activity that cannot be achieved in this position, but not in the process.

Signatera hat itself as the main ones used MRD-Test in the United States established, including more than 100 experts published in various publications. The test, which is personalized by your patients, uses the zircular tumor DNA, a residual study will recognize and quantify. Soul is, Rezidive früher your identifizieren and Behandlingsentscheidungen to optimize. Medicare’s test for more credits and immunotherapy treatment for solid tumors has been left out.

Natera mit Sitz in Austin, Texas, specializes in free DNA and gentlemen with Schwerpunkt on Onkologie, Frauengesundheit and Organgesundheit. The external staff approves the ISO 13485 certification and the CAP certification as a CLIA certification.

The press conferences are aimed at sending out the press, which reflects the broader context of the time of the Veröffentlichung. Once we’ve done this, it’s a small representation of how this decommissioning works. If there are a number of risks and feelings of insecurity, it may be that the tatsächlichen are very much absent, a sense of self-sufficiency, safety and quality of life.

This article is based on a Natera, Inc. press conference.

In other cases, Natera Inc. reported. a quarter quote of US$439.8 million, was a 64% increase over time. The unit that underwent a German analysis of the oncological test volume and 137,000 tests was a scaffolding of 54% based on previous research. The Gross Margin achieved a turnover of 62% and generated a cash flow of US$34.5 million. This robust funding source has corrected an economic forecast for the gesamtjahr of US$1.61 to US$1.64 million.

Analysts are positive about this Entwicklungen reaction. TD Cowen, Baird and Jefferies have all received positive reactions to Natera’s action and their Kursziele-angehoben. TD Cowen had a price at 175 US dollars, Baird at 160 US dollars and Jefferies at 182 US dollars, the Vertrauen in Nateras agent Erfolg and more Wachstum zum Ausdruck brought.

After the product of the Signatera-Test has been tested, it is possible that there is a very good treatment in the treatment of body medicines and the benefits of chemotherapy at Darmkrebs. The message of another message is a strong Leistung in the Frauengesundheit, a einschließlich of the einführung of the fetal RhD tests. Trotz Herausforderungen mit private Kostenträgern and möglichen feiertagsbedingten Störungen im vierten Quartal sieht Natera erhebliche Wachstumschansen with über 100 laufende Studien.

InvestingPro Acknowledgment

Trotz des Jüngsten Rechtlichen Rückschlags Hat Natera (NASDAQ: NTRA) een strandtliche marktdynamic experiences. Laut InvestingPro-Daten have partnered with a performance-oriented brand, with an average trend of 204.11% in years and started 167.02% of years. This strong Performance mirror is broader, the Action traded after 52-Wochen-Hoch, but 95.3% of these highs are supported.

The financial knowledge of the Unternehmens-zeichnen a Bild rapiden Wachstums inmitten von Herausforderungen. After the Umsatzwachstum, the termination of 54.94% for the last month, which the Umsatzwachstum underwent in the quarter of 2024, is 63.9% erreichte. It is a matter of time with the market präsenz of the Unternehmens und der zunehmenden Akzeptanz seines Signatera-Tests, who is my article.

If you say that the Natera is still not profitable, with a negative employee of US$242.09 million in the last month of the month. If you work with the InvestingPro tip, you know that the analysts don’t know that their third-party partners can make even more profits. Trotzdem has had another InvestingPro tip, of which 7 analysts had a potential financial advantage in their profit forecasts for the coming period after correcting the results.

For those years, if you make one of the most interesting analyses, with InvestingPro you can get 16 other tips for the future, an overview of the financial prosperity and market position of the external economies. This expertise can be aimed at the legitimate functioning of companies and the supervision of the internal sector in the gene testing industry that goes beyond that.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.